1-20 of 655 results for subject:"Joint Committee on Vaccination and Immunisation"
Librarians' tools
- Search time
- 0.341 seconds
- Solr query time
- 0.005 seconds
- Search query
- subject:"Joint Committee on Vaccination and Immunisation"
- We searched for
- subject_t:"Joint Committee on Vaccination and Immunisation" OR subject_t:JCVI OR subject_t:"Joint Committee on Vaccination and Immunization" OR subject_ses:41565
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, if he will publish the findings and recommendations of the JCVI’s review of meningococcal B vaccination policy for adolescents and young adults.
To ask the Secretary of State for Health and Social Care, if he will publish the findings and recommendations of the JCVI’s review of meningococcal B vaccination policy for adolescents and young adults.
The Joint Committee on Vaccination and Immunisation (JCVI) is an expert scientific advisory committee that advises the Government on eligibility for vaccination and immunisation programmes. The JCVI has been consulted on the immediate vaccine response to the outbreak and clinical effectiveness of potential future outbreak response vaccination strategies.
The JCVI holds three committee meetings a year, usually on the first Wednesday of February, June and October. The draft minutes of each meeting will be published within six weeks of the meeting. In some circumstances, when the frequency of meetings is increased, it may not be possible to upload meeting minutes within six weeks.
On 17 March, my Rt Hon. Friend, the Secretary of State for Health and Social Care, also announced to the House of Commons that the JCVI has been asked to re-examine eligibility for meningitis vaccines to assess, for example, an expanded offer to older children and/or young adults. The JCVI will provide updated advice to the Department this summer around whether, and to what extent, a vaccine programme for older children and/or young adults would be clinically effective as well as an assessment of the cost-effectiveness of such a vaccination programme.
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 5 February (HL13800), whether they plan to conduct periodic reviews of the Joint Committee on Vaccination and Immunisation's cost-effectiveness methodology to ensure that it remains up-to-date and appropriate.
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 5 February (HL13800), whether they plan to conduct periodic reviews of the Joint Committee on Vaccination and Immunisation's cost-effectiveness methodology to ensure that it remains up-to-date and appropriate.
We have one of the most comprehensive vaccination programmes in the world. Our approach to evaluating vaccination programmes is informed by expert recommendations and advice from the Joint Committee on Vaccination and Immunisation (JCVI). Working closely with the UK Health Security Agency‑based JCVI secretariat, the Department ensures that the cost-effectiveness methodology for assessing vaccination programmes continues to enable the committee to advise on programmes that deliver the greatest health benefit to the greatest number of people.
The Department maintains oversight of this methodology on an ongoing basis, with particular focus when the range of available evidence and underlying evidence landscape changes over time. Those changes may arise from time to time at irregular intervals, and so it is unlikely to be helpful to review the methodology at fixed and regular intervals.
To ask His Majesty's Government, further to the Joint Committee on Vaccination and Immunisation’s (JCVI’s) advice in November 2024 to expand eligibility for the shingles vaccination programme to include people aged 80 and over, what assessment they have made of the impact of delays in implementation on those with comorbidities...
To ask His Majesty's Government, further to the Joint Committee on Vaccination and Immunisation’s (JCVI’s) advice in November 2024 to expand eligibility for the shingles vaccination programme to include people aged 80 and over, what assessment they have made of the impact of delays in implementation on those with comorbidities...
Currently, adults become eligible for their shingles vaccination when they turn 65 or 70 years of age, and they remain eligible until their 79th birthday. Adults who are severely immunosuppressed, and therefore most at risk of serious illness and complications from shingles, are eligible from 18 years old and do not have an upper age limit.
The shingles vaccination programme has been in place since 2013, and therefore there will be a significant portion of adults currently aged 80 years old and over who were offered, and received, Zostavax, the previous shingles vaccine. All those who were born after 1 September 1933 would have been offered a vaccine in the programme.
In November 2024, the Joint Committee on Vaccination and Immunisation provided advice to the Government on eligibility for the shingles vaccination programme. This included advice that the Government should consider expanding the shingles vaccination offer to include older adult cohorts aged 80 years old and over. The Government is carefully considering this advice as it sets the policy on who should be offered shingles vaccinations in the future.
To ask His Majesty's Government what evidence, analysis or expert advice Ministers relied on in concluding that broadening the scope of health technology assessments for vaccines to include wider economic and societal impacts is unnecessary; and whether this conclusion was informed by any assessment of the capability and remit of...
To ask His Majesty's Government what evidence, analysis or expert advice Ministers relied on in concluding that broadening the scope of health technology assessments for vaccines to include wider economic and societal impacts is unnecessary; and whether this conclusion was informed by any assessment of the capability and remit of...
We are proud to have one of the most comprehensive vaccination programmes in the world. Our approach to evaluating vaccination programmes, underpinned by recommendations and advice from the Joint Committee on Vaccination and Immunisation (JCVI), is grounded in rigorous and evidence-led cost-effectiveness analysis, and ensures that decisions are objective, consistent, and based on high-quality data on health benefits and costs.
Basing our approach on these factors avoids the uncertainty of less direct benefits, where the evidence and therefore the decision is likely to be less defensible. This approach is also informed by previous work on this topic.
For example, earlier work by the independent Cost-Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP) considered, amongst other things, whether wider socio-economic impacts should be included in the framework used to assess the cost-effectiveness of vaccines. CEMIPP conducted a consultation as part of their wider work and drew upon a broad body of expert opinion. The group concluded that wider socio-economic impacts should not be included in vaccine cost-effectiveness assessments unless doing so becomes standard practice across all health technology assessments.
Additionally, in 2022, the National Institute for Health and Care Excellence (NICE) undertook a detailed appraisal of whether it should broaden the perspective it uses in its economic evaluations, including consideration of wider societal impacts. Following this review, and after examining both international comparisons, and the significant methodological and ethical challenges involved, NICE’s Board concluded that it should retain its current approach of using a health-sector perspective routinely, but with the flexibility to include wider societal benefits when they are especially relevant.
Whilst the expertise of the JCVI rightly centres on disease burden, vaccine efficacy, health outcomes and health-related costs, as outlined this is not a key reason for why the cost-effectiveness methodology for vaccines does not formally take into consideration wider socio-economic benefits.
To ask the Secretary of State for Health and Social Care, when the Joint Committee on Vaccination and Immunisation will next consider the potential merits of offering the Meningitis B vaccine to teenagers on the NHS.
To ask the Secretary of State for Health and Social Care, when the Joint Committee on Vaccination and Immunisation will next consider the potential merits of offering the Meningitis B vaccine to teenagers on the NHS.
The Joint Committee on Vaccination and Immunisation (JCVI) meningococcal sub-committee have met several times over 2024 and 2025 to discuss the meningococcal vaccination programme. In June 2025, the sub-committee noted that when available, they would like to review a model evaluating the impact of the Meningitis B (MenB) vaccination when given in a teenage programme in a two-dose schedule, including impact on meningococcal disease and gonorrhoea.
In 2013, the JCVI advised that the cost-effectiveness of an adolescent MenB vaccination programme would be dependent on the impact of the vaccine on protection against meningococcal carriage, which was uncertain at the time. Since this advice was published, the JCVI has continued to review the MenB vaccination programme. Recent evidence, discussed by the JCVI meningococcal sub-committee in March 2025, indicated that MenB vaccination in adolescents has little to no effect on meningococcal carriage.
Letter dated 19/01/2026 from Baroness Merron to Peers regarding questions raised during a debate on plans to include wider societal and economic benefits within the vaccine health technology assessment: action to include wider benefits, human capital impact assessments, eligibility for vaccination amongst older adults, and vaccination uptake. 4p.
Letter dated 19/01/2026 from Baroness Merron to Peers regarding questions raised during a debate on plans to include wider societal and economic benefits within the vaccine health technology assessment: action to include wider benefits, human capital impact assessments, eligibility for vaccination amongst older adults, and vaccination uptake. 4p.
Lords question for short debate on what plans they have to include wider societal and economic benefits within the vaccine health technology assessment, rather than limiting evaluation solely to clinical outcomes.
Lords question for short debate on what plans they have to include wider societal and economic benefits within the vaccine health technology assessment, rather than limiting evaluation solely to clinical outcomes.
My Lords, I was delighted to secure this debate as this is a subject of significant importance and one in which I have a close interest. Health and economic growth are rightly identified by the Government as two of their central priorities and they sit at the core of the...
My Lords, I was delighted to secure this debate as this is a subject of significant importance and one in which I have a close interest. Health and economic growth are rightly identified by the Government as two of their central priorities and they sit at the core of the...
My Lords, the noble Baroness, Lady Ritchie, has just given an utterly compelling speech on the subject of the debate today. I do not want to repeat the points she has made; they are completely convincing. Instead, I want to build on her arguments from my experience as a Health...
My Lords, the noble Baroness, Lady Ritchie, has just given an utterly compelling speech on the subject of the debate today. I do not want to repeat the points she has made; they are completely convincing. Instead, I want to build on her arguments from my experience as a Health...
My Lords, I thank my noble friend Lady Ritchie for arranging for us to have this debate today. It could not be at a more important time for us.
Vaccines are one of the clearest examples that we have of prevention working well. They stop illness before it starts, they reduce...
My Lords, I thank my noble friend Lady Ritchie for arranging for us to have this debate today. It could not be at a more important time for us.
Vaccines are one of the clearest examples that we have of prevention working well. They stop illness before it starts, they reduce...
My Lords, some weeks ago, the noble Baroness, Lady Ritchie of Downpatrick, tabled a Written Question on this subject. With great respect to the Minister, her response was not a strong one: it merely suggested the possibility of considerations such as productivity costs being highlighted by the Joint Committee on...
My Lords, some weeks ago, the noble Baroness, Lady Ritchie of Downpatrick, tabled a Written Question on this subject. With great respect to the Minister, her response was not a strong one: it merely suggested the possibility of considerations such as productivity costs being highlighted by the Joint Committee on...
My Lords, I thank the noble Baroness, Lady Ritchie of Downpatrick, for securing this timely and important debate and for the eloquent way in which she laid out her argument. We saw the value of vaccines during the Covid-19 pandemic. Millions
of people rolled up their sleeves, with the impact...
My Lords, I thank the noble Baroness, Lady Ritchie of Downpatrick, for securing this timely and important debate and for the eloquent way in which she laid out her argument. We saw the value of vaccines during the Covid-19 pandemic. Millions
of people rolled up their sleeves, with the impact...
My Lords, I am most grateful to my noble friend Lady Ritchie for her thorough introduction and for securing this debate. I am also grateful to all noble Lords for their considered contributions. The subject of today’s debate reflects my noble friend’s steadfast commitment to improving access to immunisation and...
My Lords, I am most grateful to my noble friend Lady Ritchie for her thorough introduction and for securing this debate. I am also grateful to all noble Lords for their considered contributions. The subject of today’s debate reflects my noble friend’s steadfast commitment to improving access to immunisation and...
Before my noble friend sits down, I ask that she and her ministerial colleagues in the Department of Health and Social Care give particular attention to establishing the independent committee to evaluate the existing vaccine health technology assessment process so that the impact of vaccines on the economy, education and...
Before my noble friend sits down, I ask that she and her ministerial colleagues in the Department of Health and Social Care give particular attention to establishing the independent committee to evaluate the existing vaccine health technology assessment process so that the impact of vaccines on the economy, education and...
I understand why my noble friend is raising that, but NICE is seen as a world leader in that regard and has processes in place to review its processes and methods to ensure that they remain fit for purpose. I am not entirely convinced, as my noble friend will see,...
I understand why my noble friend is raising that, but NICE is seen as a world leader in that regard and has processes in place to review its processes and methods to ensure that they remain fit for purpose. I am not entirely convinced, as my noble friend will see,...
To ask the Secretary of State for Health and Social Care, when the Joint Committee on Vaccination and Immunisation last reviewed the cost-effectiveness model for providing the Meningitis B vaccine to teenagers; and whether his Department plans to commission an updated model.
To ask the Secretary of State for Health and Social Care, when the Joint Committee on Vaccination and Immunisation last reviewed the cost-effectiveness model for providing the Meningitis B vaccine to teenagers; and whether his Department plans to commission an updated model.
In 2013, the Joint Committee on Vaccination and Immunisation (JCVI) advised that the cost-effectiveness of an adolescent Meningitis B (MenB) vaccination programme would be dependent on the impact of the vaccine on protection against meningococcal carriage, which was uncertain at the time. Since this advice was published, the JCVI has continued to review the MenB vaccination programme. Recent evidence, discussed by the JCVI meningococcal sub-committee in March 2025, indicated that MenB vaccination in adolescents has little to no effect on meningococcal carriage.
The sub-committee noted that when available, they would like to review a model evaluating the impact of MenB vaccine when given in a teenage programme in a two-dose schedule, including impact on meningococcal disease and gonorrhoea.
To ask the Secretary of State for Health and Social Care, how frequently his Department and the Joint Committee on Vaccination and Immunisation review eligibility criteria for the COVID-19 vaccination programme.
To ask the Secretary of State for Health and Social Care, how frequently his Department and the Joint Committee on Vaccination and Immunisation review eligibility criteria for the COVID-19 vaccination programme.
The Government’s policy on the groups eligible for vaccination programmes, including for the COVID-19 vaccination programme, is based on the advice of the independent expert body, the Joint Committee on Vaccination and Immunisation (JCVI). The JCVI meets three times a year, in February, June, and October.
My hon. Friend the Parliamentary Under-Secretary of State for Public Health and Prevention (Ashley Dalton MP) made the following Statement:
His Majesty’s Government (HMG) is committed to protecting people most vulnerable to COVID-19 through vaccination as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI).
On 13 November 2024, the...
My hon. Friend the Parliamentary Under-Secretary of State for Public Health and Prevention (Ashley Dalton MP) made the following Statement:
His Majesty’s Government (HMG) is committed to protecting people most vulnerable to COVID-19 through vaccination as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI).
On 13 November 2024, the...
His Majesty’s Government (HMG) is committed to protecting people most vulnerable to COVID-19 through vaccination as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI).
On 13 November 2024, the JCVI published advice on the COVID-19 vaccination programme for spring 2025, autumn 2025 and spring 2026. On 26 June...
His Majesty’s Government (HMG) is committed to protecting people most vulnerable to COVID-19 through vaccination as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI).
On 13 November 2024, the JCVI published advice on the COVID-19 vaccination programme for spring 2025, autumn 2025 and spring 2026. On 26 June...